Pipeline

headers-67.png
headers-69.png
icon.png

The Fever Encounter:

A few sentences explaining the fever encounter.

Pipeline.png

> 10 M deaths &

$100 trillion

MeMed BV® is a pioneering immune-based protein test that provides physicians with an indispensable tool to distinguish between bacterial and viral infections. MeMed BV™ has been validated by an unprecedented level of high-quality clinical data from more than 20,000 patients and multinational, double-blind clinical studies, which have been published in leading peer-reviewed journals. The test has over 90% sensitivity and specificity (NPV>98%) across multiple pathogens1–4

Uncertainty leads to Antibiotic overuse and Antimicrobial Resistance

Pipeline2.png

Accurate triage at ED reduces costs & saves lives2,3

1.7 million adults develop severe infections in the US annually1

270,000 deaths & $41B is spent in the US annually1

Initial data from a prospective study shows that a new signature by MeMed can be a valuable resource for early detection of disease severity and progression for patients with severe COVID-19. Using the MeMed COVID-19 Severity test, researchers measured IP-10 levels twice a day over the course of a month in 52 SARS-CoV-2 positive patients, 26 of whom developed severe COVID-19. This revealed that severe patients had very high median IP-10 levels (1,190 pg/mL) compared to the median IP-10 levels of the non-severe group (328 pg/mL).

Pipeline3.png

Timely and personalized treatment with immunomodulatory drugs can save lives

Severe hyperinflammatory immune response can lead to mortality in severe infections including COVID-19 patients and other diseases.

Initial data from a prospective study shows that serial and rapid measurements of IP-10 can be a valuable resource for monitoring inflammatory status and personalizing treatment strategies for severe COVID-19 patients treated with corticosteroids. 

Dilemma 1:

O’Neill, The AMR Report, 2016

Dilemma 2:

https://www.cdc.gov/sepsis/clinicaltools/index.html 

https://journals.lww.com/ccmjournal/Fulltext/2020/03000/Sepsis_Among_Medicare_Beneficiaries 

https://www.nejm.org/doi/full/10.1056/nejmoa1703058

Dilemma 3:

Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017 Jul;39(5):517-528. doi: 10.1007/s00281-017-0639-8. Epub 2017 May 29. PMID: 28555385.

Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28. PMID: 

Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32. doi: 10.1128/MMBR.05015-11. PMID: 22390970; PMCID: PMC3294426.32346093; PMCID: PMC7187672.